Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtypes of non-
Hodgkin lymphoma. It is a heterogeneous disease, and a distinctive subgroup of patients …

There have been two major developments over the last decade that has led to
improvements in outcome and longer survival for patients with diffuse large B-cell lymphoma …

Abstract Treatment with rituximab plus a regimen of cyclophosphamide, doxorubicin,
vincristine and prednisolone (CHOP) for patients with diffuse large B-cell lymphoma …

Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype, is localized
in 25% to 30% of patients. Prognosis in patients with limited-stage DLBCL (LS-DLBCL) is …

Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant
lymphoma in the Western world. It has an aggressive natural history, with a median survival …

Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma and is not localized
in 70% of the cases. Even if the clinical picture, the morphologic aspect, and the prognostic …

Diffuse large B‐cell lymphoma (DLBCL) is the most commonly occurring form of non‐
Hodgkin lymphoma in the western world. Until the mid 1990s the incidence of DLBCL …

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin
lymphoma in the United States. Historically, radiation therapy (RT) was the primary treatment …

Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin
lymphoma, is an aggressive and biologically heterogeneous disease. Risk stratifi cation and …

Outcome in diffuse large B-cell lymphoma (DLBCL) has improved over the last decade and
will likely improve further with the introduction of novel agents. At the present time, clinical …